LuAE 58054 success in Phase II study for Alzheimers Disease

Data was announced by Lundbeck from a 278-patient Phase II proof of concept study that showed that LuAE 58054 has met its primary cognition-based endpoint.In the study, adding a fixed dose of Lu AE 58054 to 10mg/day of the acetylcholinesterase inhibitor donepezil resulted in a significantly greater improvement in cognition as measured by the ADAS-Cog scale over a 24-week treatment period in patients with moderate disease compared with placebo plus donepezil.Competitors will include SB 742457 from GSK which has been tested in three Phase II trials as monotherapy and in combination with donepezil in mild to modeate Alzheimers Disease.